Peter Ordentlich
Founder chez SYNDAX PHARMACEUTICALS, INC.
Fortune : 6 307 $ au 31/03/2024
Profil
Peter Ordentlich is the founder of Syndax Pharmaceuticals, Inc., which was founded in 2005.
He currently holds the title of Chief Scientific Officer at Syndax Pharmaceuticals, Inc. Dr. Ordentlich also held the position of Principal at The Salk Institute for Biological Studies and Research Scientist at X-Ceptor Therapeutics, Inc. In terms of education, Dr. Ordentlich obtained undergraduate and doctorate degrees from the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/02/2023 | 265 ( 0,00% ) | 6 307 $ | 31/03/2024 |
Postes actifs de Peter Ordentlich
| Sociétés | Poste | Début |
|---|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Founder | 11/10/2005 |
Anciens postes connus de Peter Ordentlich
| Sociétés | Poste | Fin |
|---|---|---|
X-Ceptor Therapeutics, Inc.
 X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - |
| The Salk Institute for Biological Studies | Corporate Officer/Principal | - |
Formation de Peter Ordentlich
| University of Pennsylvania | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
